Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors
Restoring oxygenation in hypoxic tumors might lead to favorable oncological outcome of patients if combined with standard multimodal therapy regimens. Here the authors report a phase Ib clinical trial of anti-hypoxic myo-inositol trispyrophosphate (ITPP) in hepato-pancreato-biliary neoplasms.
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2021-06-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-021-24069-w |
| id |
doaj-cd2ec9ef8ede4523a0cca213868f4458 |
|---|---|
| record_format |
Article |
| spelling |
doaj-cd2ec9ef8ede4523a0cca213868f44582021-06-27T11:13:45ZengNature Publishing GroupNature Communications2041-17232021-06-0112111210.1038/s41467-021-24069-wPhase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumorsMarcel A. Schneider0Michael Linecker1Ralph Fritsch2Urs J. Muehlematter3Daniel Stocker4Bernhard Pestalozzi5Panagiotis Samaras6Alexander Jetter7Philipp Kron8Henrik Petrowsky9Claude Nicolau10Jean-Marie Lehn11Bostjan Humar12Rolf Graf13Pierre-Alain Clavien14Perparim Limani15Swiss Hepato-Pancreato-Biliary (HPB) and Transplantation Center, University Hospital ZurichSwiss Hepato-Pancreato-Biliary (HPB) and Transplantation Center, University Hospital ZurichSwiss Hepato-Pancreato-Biliary (HPB) and Transplantation Center, University Hospital ZurichInstitute of Interventional and Diagnostic Radiology, University Hospital ZurichInstitute of Interventional and Diagnostic Radiology, University Hospital ZurichSwiss Hepato-Pancreato-Biliary (HPB) and Transplantation Center, University Hospital ZurichOncology Center, Hirslanden Hospital ZurichDepartment of Clinical Pharmacology and Toxicology, University Hospital ZurichSwiss Hepato-Pancreato-Biliary (HPB) and Transplantation Center, University Hospital ZurichSwiss Hepato-Pancreato-Biliary (HPB) and Transplantation Center, University Hospital ZurichFriedman School of Nutrition Science and Policy, Tufts UniversityInstitut de Science et d’Ingénierie Supramoléculaires (ISIS), Université de Strasbourg, 8 allée Gaspard MongeSwiss Hepato-Pancreato-Biliary (HPB) and Transplantation Center, University Hospital ZurichSwiss Hepato-Pancreato-Biliary (HPB) and Transplantation Center, University Hospital ZurichSwiss Hepato-Pancreato-Biliary (HPB) and Transplantation Center, University Hospital ZurichSwiss Hepato-Pancreato-Biliary (HPB) and Transplantation Center, University Hospital ZurichRestoring oxygenation in hypoxic tumors might lead to favorable oncological outcome of patients if combined with standard multimodal therapy regimens. Here the authors report a phase Ib clinical trial of anti-hypoxic myo-inositol trispyrophosphate (ITPP) in hepato-pancreato-biliary neoplasms.https://doi.org/10.1038/s41467-021-24069-w |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Marcel A. Schneider Michael Linecker Ralph Fritsch Urs J. Muehlematter Daniel Stocker Bernhard Pestalozzi Panagiotis Samaras Alexander Jetter Philipp Kron Henrik Petrowsky Claude Nicolau Jean-Marie Lehn Bostjan Humar Rolf Graf Pierre-Alain Clavien Perparim Limani |
| spellingShingle |
Marcel A. Schneider Michael Linecker Ralph Fritsch Urs J. Muehlematter Daniel Stocker Bernhard Pestalozzi Panagiotis Samaras Alexander Jetter Philipp Kron Henrik Petrowsky Claude Nicolau Jean-Marie Lehn Bostjan Humar Rolf Graf Pierre-Alain Clavien Perparim Limani Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors Nature Communications |
| author_facet |
Marcel A. Schneider Michael Linecker Ralph Fritsch Urs J. Muehlematter Daniel Stocker Bernhard Pestalozzi Panagiotis Samaras Alexander Jetter Philipp Kron Henrik Petrowsky Claude Nicolau Jean-Marie Lehn Bostjan Humar Rolf Graf Pierre-Alain Clavien Perparim Limani |
| author_sort |
Marcel A. Schneider |
| title |
Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors |
| title_short |
Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors |
| title_full |
Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors |
| title_fullStr |
Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors |
| title_full_unstemmed |
Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors |
| title_sort |
phase ib dose-escalation study of the hypoxia-modifier myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2021-06-01 |
| description |
Restoring oxygenation in hypoxic tumors might lead to favorable oncological outcome of patients if combined with standard multimodal therapy regimens. Here the authors report a phase Ib clinical trial of anti-hypoxic myo-inositol trispyrophosphate (ITPP) in hepato-pancreato-biliary neoplasms. |
| url |
https://doi.org/10.1038/s41467-021-24069-w |
| work_keys_str_mv |
AT marcelaschneider phaseibdoseescalationstudyofthehypoxiamodifiermyoinositoltrispyrophosphateinpatientswithhepatopancreatobiliarytumors AT michaellinecker phaseibdoseescalationstudyofthehypoxiamodifiermyoinositoltrispyrophosphateinpatientswithhepatopancreatobiliarytumors AT ralphfritsch phaseibdoseescalationstudyofthehypoxiamodifiermyoinositoltrispyrophosphateinpatientswithhepatopancreatobiliarytumors AT ursjmuehlematter phaseibdoseescalationstudyofthehypoxiamodifiermyoinositoltrispyrophosphateinpatientswithhepatopancreatobiliarytumors AT danielstocker phaseibdoseescalationstudyofthehypoxiamodifiermyoinositoltrispyrophosphateinpatientswithhepatopancreatobiliarytumors AT bernhardpestalozzi phaseibdoseescalationstudyofthehypoxiamodifiermyoinositoltrispyrophosphateinpatientswithhepatopancreatobiliarytumors AT panagiotissamaras phaseibdoseescalationstudyofthehypoxiamodifiermyoinositoltrispyrophosphateinpatientswithhepatopancreatobiliarytumors AT alexanderjetter phaseibdoseescalationstudyofthehypoxiamodifiermyoinositoltrispyrophosphateinpatientswithhepatopancreatobiliarytumors AT philippkron phaseibdoseescalationstudyofthehypoxiamodifiermyoinositoltrispyrophosphateinpatientswithhepatopancreatobiliarytumors AT henrikpetrowsky phaseibdoseescalationstudyofthehypoxiamodifiermyoinositoltrispyrophosphateinpatientswithhepatopancreatobiliarytumors AT claudenicolau phaseibdoseescalationstudyofthehypoxiamodifiermyoinositoltrispyrophosphateinpatientswithhepatopancreatobiliarytumors AT jeanmarielehn phaseibdoseescalationstudyofthehypoxiamodifiermyoinositoltrispyrophosphateinpatientswithhepatopancreatobiliarytumors AT bostjanhumar phaseibdoseescalationstudyofthehypoxiamodifiermyoinositoltrispyrophosphateinpatientswithhepatopancreatobiliarytumors AT rolfgraf phaseibdoseescalationstudyofthehypoxiamodifiermyoinositoltrispyrophosphateinpatientswithhepatopancreatobiliarytumors AT pierrealainclavien phaseibdoseescalationstudyofthehypoxiamodifiermyoinositoltrispyrophosphateinpatientswithhepatopancreatobiliarytumors AT perparimlimani phaseibdoseescalationstudyofthehypoxiamodifiermyoinositoltrispyrophosphateinpatientswithhepatopancreatobiliarytumors |
| _version_ |
1721358188067946496 |